Stock listing
OTC:CASIF CASI Pharmaceuticals, Inc. Stock
Follow CASI Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · OTC:CASIF
$0.10 USD +0.00 (+0.1%)
Close on Nov 20, 2026
Past year -91.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits- Day range
- $0.10 – $0.10 USDNov 20, 2026
- Volume
- 15,012 sharesNov 20, 2026
- Market cap
- $2.06M USDAt the close on Nov 20, 2026 · price × 20.56M shares outstanding
- 52-week range
- $0.05 – $1.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $223 USDMedian day 700 shares · 6 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:CASIF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|
| $0.10 | +0.00 | +0.1% | $0.10 | $0.10 | $0.10 | 15,012 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 70 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 10,000 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 2 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 1,575 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 887 |
|---|
| $0.10 | 0.00 | -0.1% | $0.10 | $0.10 | $0.10 | 18,434 |
|---|
| $0.10 | -0.01 | -9.0% | $0.10 | $0.10 | $0.10 | 726 |
|---|
| $0.11 | +0.01 | +9.9% | $0.11 | $0.11 | $0.11 | 709 |
|---|
| $0.10 | +0.00 | +0.1% | $0.10 | $0.10 | $0.10 | 50 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 189 |
|---|
| $0.10 | -0.015 | -12.9% | $0.105 | $0.105 | $0.10 | 145 |
|---|
| $0.115 | -0.015 | -11.8% | $0.133 | $0.133 | $0.115 | 4,892 |
|---|
| $0.13 | +0.013 | +10.7% | $0.13 | $0.13 | $0.13 | 258 |
|---|
| $0.118 | +0.017 | +17.5% | $0.11 | $0.118 | $0.11 | 356 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 252 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 625 |
|---|
| $0.10 | 0.00 | 0.0% | $0.12 | $0.12 | $0.10 | 4,100 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 5,200 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 900 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 500 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 700 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 400 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 700 |
|---|
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.10 | 300 |
|---|
| $0.10 | -0.01 | -9.1% | $0.11 | $0.11 | $0.10 | 2,300 |
|---|
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 2,100 |
|---|
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 200 |
|---|
| $0.11 | 0.00 | 0.0% | $0.11 | $0.13 | $0.11 | 4,500 |
|---|
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 3,000 |
|---|
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 800 |
|---|
| $0.11 | -0.01 | -8.3% | $0.11 | $0.11 | $0.11 | 200 |
|---|
| $0.12 | 0.00 | 0.0% | $0.12 | $0.12 | $0.12 | 1,000 |
|---|
| $0.12 | +0.01 | +9.1% | $0.11 | $0.12 | $0.11 | 3,300 |
|---|
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 50 |
|---|
| $0.11 | -0.01 | -8.3% | $0.11 | $0.11 | $0.11 | 300 |
|---|
| $0.12 | -0.01 | -7.7% | $0.13 | $0.13 | $0.12 | 1,300 |
|---|
| $0.13 | -0.03 | -18.8% | $0.13 | $0.13 | $0.13 | 600 |
|---|
| $0.16 | 0.00 | 0.0% | $0.16 | $0.16 | $0.16 | 0 |
|---|
| $0.16 | +0.03 | +23.1% | $0.13 | $0.16 | $0.13 | 2,800 |
|---|
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 300 |
|---|
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 700 |
|---|
| $0.13 | -0.01 | -7.1% | $0.13 | $0.14 | $0.13 | 400 |
|---|
| $0.14 | +0.01 | +7.7% | $0.13 | $0.14 | $0.13 | 1,700 |
|---|
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 0 |
|---|
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 58 |
|---|
| $0.13 | -0.01 | -7.1% | $0.13 | $0.14 | $0.13 | 2,500 |
|---|
| $0.14 | 0.00 | 0.0% | $0.14 | $0.14 | $0.14 | 0 |
|---|
| $0.14 | +0.01 | +7.7% | $0.14 | $0.14 | $0.14 | 3,000 |
|---|
| $0.13 | -0.01 | -7.1% | $0.14 | $0.14 | $0.13 | 6,300 |
|---|
| $0.14 | -0.01 | -6.7% | $0.14 | $0.14 | $0.14 | 12,200 |
|---|
| $0.15 | 0.00 | 0.0% | $0.15 | $0.15 | $0.15 | 700 |
|---|
| $0.15 | +0.01 | +7.1% | $0.15 | $0.15 | $0.15 | 700 |
|---|
| $0.14 | +0.01 | +7.7% | $0.14 | $0.14 | $0.14 | 1,500 |
|---|
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 0 |
|---|
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 100 |
|---|
| $0.13 | -0.01 | -7.1% | $0.13 | $0.13 | $0.13 | 1,700 |
|---|
| $0.14 | +0.01 | +7.7% | $0.14 | $0.14 | $0.14 | 100 |
|---|
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 0 |
|---|
| $0.13 | -0.01 | -7.1% | $0.13 | $0.13 | $0.13 | 100 |
|---|
| $0.14 | +0.01 | +7.7% | $0.13 | $0.14 | $0.13 | 500 |
|---|
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 0 |
|---|
| $0.13 | 0.00 | 0.0% | $0.13 | $0.13 | $0.13 | 1,200 |
|---|
Splits
2 splits since 2010 · OTC:CASIF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|
| 1-for-10 | Consolidation |
|---|
| 1-for-11 | Consolidation |
|---|
- Ticker
- OTC:CASIF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
CASI Pharmaceuticals, Inc. on 6ix
- Calls
- 1 call with a replay · 1 with a transcript · latest Mar 12, 2021
- Decks
- 22 decks · latest January 2026
Valuation
EV/sales 1.9× against a median of −11.6×: the highest of 4 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $38.79M USD
- P/E
- Loss
- EV/sales
- 1.9×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- 60.0%
- Operating margin
- −191.0%
- Net margin
- −218.6%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- -0.07
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.41 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|
| Chunhua Wang | Chief Operating Officer |
|---|
| Wei Gao | General Counsel |
|---|
| Junping Chen | Chief Medical Officer |
|---|
| Kun Qian | Global Controller |
|---|
| Wei-Wu He | Executive Chairman |
|---|
Board
| Director | Role |
|---|
| Wei-Wu He | Executive Chairman |
|---|
| Alex Wu | Director |
|---|
| Frank Su | Director |
|---|
| James Huang | Director |
|---|
| Thomas Folinsbee | Director |
|---|
| Xuebo Zeng | Director |
|---|
Events
Results days
| Quarter | Results | Share move |
|---|
| Q1 2026 | May 15, 2026 · Before open | +7.1% |
|---|
| Q3 2025 | Nov 14, 2025 · After close | −5.6% |
|---|
| Q2 2025 | Aug 29, 2025 · After close | −0.4% |
|---|
| Q1 2025 | May 16, 2025 · Before open | +7.2% |
|---|
| Q3 2024 | Nov 15, 2024 · Before open | −9.3% |
|---|
| Q2 2024 | Aug 16, 2024 · Before open | 0.0% |
|---|
| Q1 2024 | May 14, 2024 | +27.2% |
|---|
| Q4 2023 | Mar 28, 2024 · Before open | +20.3% |
|---|
| Q3 2023 | Nov 14, 2023 · Before open | +1.1% |
|---|
| Q2 2023 | Aug 11, 2023 · Before open | +3.6% |
|---|
All 19 quarters
| Quarter | Results | Share move |
|---|
| Q1 2023 | May 17, 2023 · Before open | −7.6% |
|---|
| Q3 2022 | Nov 14, 2022 · Before open | −4.5% |
|---|
| Q2 2022 | Aug 12, 2022 · Before open | −10.8% |
|---|
| Q1 2022 | May 12, 2022 · Before open | −6.1% |
|---|
| Q4 2021 | Mar 28, 2022 | +9.4% |
|---|
| Q3 2021 | Nov 12, 2021 · Before open | +2.9% |
|---|
| Q2 2021 | Aug 12, 2021 · Before open | −1.7% |
|---|
| Quarter to Mar 31, 2021 | May 13, 2021 · Before open | −2.1% |
|---|
| Quarter to Dec 31, 2020 | Mar 30, 2021 | +21.2% |
|---|
Open Events
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|
| Revenue | 20.7M | 28.5M | 33.9M | 43.1M | 30.2M | 15.1M | 4.13M | | | |
|---|
| Cost of revenue | 10.6M | 17.4M | 13.8M | 15.8M | 12.6M | 9.51M | 3.94M | 1.67M | 117.8K | 66.5K |
|---|
| Gross profit | 10.1M | 11.1M | 20.1M | 27.3M | 17.6M | 5.63M | 196.0K | -1.67M | -117.8K | -66.5K |
|---|
| Research and development | 6.31M | 8.92M | 9.86M | 16.0M | 14.4M | 11.5M | 9.75M | 8.51M | 7.60M | 4.65M |
|---|
| Selling, general and administrative | 46.6M | 23.6M | 25.4M | 23.4M | 23.7M | 19.7M | 27.3M | 18.0M | 3.16M | 4.78M |
|---|
| Operating income | -45.0M | -39.6M | -25.1M | -34.0M | -41.5M | -52.8M | -40.0M | -26.5M | -10.8M | 9.42M |
|---|
| Depreciation and amortization | 1.20M | 1.30M | 2.50M | 1.20M | 500.0K | 600.0K | 2.15M | 1.67M | 117.8K | 66.5K |
|---|
| EBITDA | -43.8M | -38.3M | -22.6M | -32.8M | -41.0M | -52.2M | -37.8M | -24.8M | -10.6M | 9.49M |
|---|
| Interest expense | 840.0K | 871.0K | 15.0K | 0 | 2.90K | 3.10K | | 8.21K | 15.0K | 33.8K |
|---|
| Income before tax | -45.9M | -38.1M | -26.3M | -37.4M | -35.8M | -47.5M | -45.4M | -27.5M | -10.8M | -9.45M |
|---|
| Income tax | | 0 | -81.0K | 1.98M | 0 | 0 | | | 15.0K | 33.8K |
|---|
| Net income | -48.1M | -39.3M | -27.0M | -41.0M | -36.7M | -48.3M | -45.4M | -27.5M | -10.8M | -9.45M |
|---|
| Earnings per share, basic | -2.59 | -2.56 | -2.02 | -3.01 | -2.69 | -4.37 | -4.73 | -3.24 | -1.75 | -1.69 |
|---|
| Earnings per share, diluted | -2.59 | -2.56 | -2.02 | -3.01 | -2.69 | -4.37 | | | | |
|---|
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|
| Cash and equivalents | 5.63M | 13.5M | 17.1M | 47.1M | 38.7M | 57.1M | 53.6M | 84.2M | 43.5M | 27.1M |
|---|
| Short-term investments | 0 | 2.62M | 12.0M | 1.46M | 9.87M | 9.31M | 625.0K | 912.2K | | |
|---|
| Receivables | 4.09M | 15.3M | 9.55M | 13.0M | 9.80M | 4.64M | 1.29M | | | |
|---|
| Inventory | 1.60M | 5.25M | 15.9M | 6.14M | 1.91M | 1.36M | 4.54M | 283.0K | | |
|---|
| Current assets | 13.5M | 39.6M | 59.3M | 73.4M | 62.0M | 74.0M | 61.5M | 92.6M | 43.8M | 27.4M |
|---|
| Property, plant and equipment | 6.97M | 7.87M | 9.24M | 11.8M | 12.7M | | | | | |
|---|
| Total assets | 25.6M | 53.7M | 75.3M | 96.2M | 138.3M | 127.7M | 102.6M | 113.4M | 45.1M | 27.7M |
|---|
| Accounts payable | 1.06M | 2.72M | 4.44M | 3.29M | 2.22M | 3.26M | 5.11M | 968.0K | 2.09M | 1.06M |
|---|
| Current liabilities | 49.7M | 36.5M | 16.7M | 17.0M | 13.2M | 7.98M | 7.95M | 3.87M | 5.06M | 1.32M |
|---|
| Long-term debt | | | 18.9M | | | | | | | |
|---|
| Total debt | 19.2M | 18.4M | 18.9M | 1.34M | 4.33M | 3.20M | 2.20M | 1.50M | 1.50M | 1.49M |
|---|
| Total liabilities | 62.9M | 51.8M | 51.1M | 29.3M | 30.3M | 24.2M | 8.97M | 3.95M | 6.56M | 6.93M |
|---|
| Shareholders' equity | -37.3M | 1.85M | 24.2M | 44.6M | 84.5M | 81.5M | 73.0M | 109.5M | 38.5M | 20.8M |
|---|
| Shares outstanding | 20.6M | 15.5M | 13.4M | 13.5M | 14.0M | 13.4M | 9.59M | 8.48M | 6.15M | 5.59M |
|---|
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|
| Cash from operations | -20.8M | -29.2M | -20.0M | -21.1M | -26.8M | -25.9M | -23.2M | -28.6M | -6.40M | -6.02M |
|---|
| Capital spending | -16.0K | -223.0K | -204.0K | -5.61M | -8.95M | -1.50M | -14.0M | -21.8M | -934.7K | -223.2K |
|---|
| Free cash flow | -20.8M | -29.4M | -20.2M | -26.7M | -35.8M | -27.4M | -37.3M | -50.4M | -7.34M | -6.25M |
|---|
| Cash from investing | 951.0K | 11.2M | -9.67M | 31.2M | -20.7M | -20.7M | -28.1M | -21.8M | -934.7K | -64.8K |
|---|
| Cash from financing | 11.3M | 15.4M | -907.0K | -3.27M | 29.6M | 47.2M | 22.0M | 92.3M | 23.7M | 28.0M |
|---|
| Dividends paid | | -718.0K | -738.0K | | | | | | | |
|---|
| Share buybacks | 0 | 0 | -278.0K | -3.27M | 0 | | | | | |
|---|
| Change in cash | -7.84M | -3.62M | -30.0M | 8.41M | -18.4M | 3.44M | -30.6M | 40.7M | 16.4M | 22.0M |
|---|
Open Financials
Filings
| Filing | Date | Type | Filed with |
|---|
| 6-K · Report of a foreign issuer | Sep 2, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 14, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 13, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 15, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 29, 2026 | Current report | SEC |
|---|
| 25-NSE | Jun 23, 2026 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 2, 2026 | Current report | SEC |
|---|
| SCHEDULE 13D/A · Big-stake notice, amended | May 18, 2026 | Big-stake notice | SEC |
|---|
| 20-F · Annual report | May 15, 2026 | Annual report | SEC |
|---|
| D | Apr 28, 2026 | Other filings | SEC |
|---|
All 157 filings
| Filing | Date | Type | Filed with |
|---|
| 3 · Initial statement of ownership | Apr 23, 2026 | Insider trade | SEC |
|---|
| NT 20-F | Apr 21, 2026 | Explanation request | SEC |
|---|
| 3 · Initial statement of ownership | Apr 20, 2026 | Insider trade | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 20, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 20, 2026 | Current report | SEC |
|---|
| 3 · Initial statement of ownership | Apr 16, 2026 | Insider trade | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 15, 2026 | Current report | SEC |
|---|
| 3 · Initial statement of ownership | Apr 13, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 7, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 3, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 3, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Mar 27, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Mar 25, 2026 | Insider trade | SEC |
|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 23, 2026 | Big-stake notice | SEC |
|---|
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
|---|
| 6-K · Report of a foreign issuer | Mar 3, 2026 | Current report | SEC |
|---|
| D | Feb 26, 2026 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 25, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 20, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 19, 2026 | Current report | SEC |
|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 10, 2026 | Current report | SEC |
|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 29, 2026 | Big-stake notice | SEC |
|---|
| D | Jan 28, 2026 | Other filings | SEC |
|---|
| D | Jan 28, 2026 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | Jan 22, 2026 | Current report | SEC |
|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 20, 2026 | Big-stake notice | SEC |
|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 20, 2026 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Jan 13, 2026 | Current report | SEC |
|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 9, 2026 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 30, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 23, 2025 | Current report | SEC |
|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 18, 2025 | Big-stake notice | SEC |
|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 17, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 11, 2025 | Current report | SEC |
|---|
| SCHEDULE 13G · Big-stake notice | Nov 26, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 19, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 14, 2025 | Current report | SEC |
|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 10, 2025 | Current report | SEC |
|---|
| SCHEDULE 13D · Big-stake notice | Sep 26, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Sep 26, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Sep 2, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 29, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 27, 2025 | Current report | SEC |
|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 4, 2025 | Current report | SEC |
|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 23, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 21, 2025 | Current report | SEC |
|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 20, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | May 20, 2025 | Current report | SEC |
|---|
| 6-K/A · Report of a foreign issuer, amended | May 20, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | May 16, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | May 14, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | May 12, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | May 7, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 9, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 3, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 3, 2025 | Current report | SEC |
|---|
| 424B5 · Prospectus | Apr 1, 2025 | Offer document | SEC |
|---|
| 20-F · Annual report | Mar 31, 2025 | Annual report | SEC |
|---|
| 6-K · Report of a foreign issuer | Mar 31, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 10, 2025 | Current report | SEC |
|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 3, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Jan 21, 2025 | Current report | SEC |
|---|
| EFFECT · Notice that a registration is effective | Jan 2, 2025 | Other filings | SEC |
|---|
| CORRESP · Letter to the SEC | Dec 30, 2024 | Other filings | SEC |
|---|
| UPLOAD · Letter from the SEC | Dec 26, 2024 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 26, 2024 | Current report | SEC |
|---|
| F-3/A · Registration statement, amended | Dec 23, 2024 | Offer document | SEC |
|---|
| F-3 · Registration statement | Dec 20, 2024 | Offer document | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 16, 2024 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 15, 2024 | Current report | SEC |
|---|
| SC 13G/A · Big-stake notice, amended | Oct 29, 2024 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Sep 12, 2024 | Current report | SEC |
|---|
| EFFECT · Notice that a registration is effective | Sep 4, 2024 | Other filings | SEC |
|---|
| CORRESP · Letter to the SEC | Aug 29, 2024 | Other filings | SEC |
|---|
| F-3/A · Registration statement, amended | Aug 29, 2024 | Offer document | SEC |
|---|
| UPLOAD · Letter from the SEC | Aug 23, 2024 | Other filings | SEC |
|---|
| F-3 · Registration statement | Aug 16, 2024 | Offer document | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 16, 2024 | Current report | SEC |
|---|
| S-8 · Registration statement for employee plans | Aug 14, 2024 | Offer document | SEC |
|---|
| SC 13D/A · Big-stake notice, amended | Aug 12, 2024 | Big-stake notice | SEC |
|---|
| SC 13G · Big-stake notice | Jul 25, 2024 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 19, 2024 | Current report | SEC |
|---|
| D | Jul 15, 2024 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 8, 2024 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 27, 2024 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 27, 2024 | Current report | SEC |
|---|
| SC 13G · Big-stake notice | Jun 20, 2024 | Big-stake notice | SEC |
|---|
| SC 13G/A · Big-stake notice, amended | Jun 11, 2024 | Big-stake notice | SEC |
|---|
| UPLOAD · Letter from the SEC | Jun 10, 2024 | Other filings | SEC |
|---|
| CORRESP · Letter to the SEC | May 30, 2024 | Other filings | SEC |
|---|
| UPLOAD · Letter from the SEC | May 22, 2024 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | May 15, 2024 | Current report | SEC |
|---|
| EFFECT · Notice that a registration is effective | May 13, 2024 | Other filings | SEC |
|---|
| CORRESP · Letter to the SEC | May 9, 2024 | Other filings | SEC |
|---|
| UPLOAD · Letter from the SEC | May 8, 2024 | Other filings | SEC |
|---|
| F-3 · Registration statement | May 3, 2024 | Offer document | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 8, 2024 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Mar 28, 2024 | Current report | SEC |
|---|
| 20-F · Annual report | Mar 28, 2024 | Annual report | SEC |
|---|
| 144 · Notice of proposed sale | Mar 15, 2024 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | Mar 13, 2024 | Current report | SEC |
|---|
| 144 · Notice of proposed sale | Mar 5, 2024 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 29, 2024 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 9, 2024 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jan 29, 2024 | Current report | SEC |
|---|
| SC 13G/A · Big-stake notice, amended | Jan 26, 2024 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 15, 2023 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 8, 2023 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 14, 2023 | Current report | SEC |
|---|
| SC 13G/A · Big-stake notice, amended | Nov 9, 2023 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 8, 2023 | Current report | SEC |
|---|
| UPLOAD · Letter from the SEC | Sep 19, 2023 | Other filings | SEC |
|---|
| CORRESP · Letter to the SEC | Aug 25, 2023 | Other filings | SEC |
|---|
| UPLOAD · Letter from the SEC | Aug 14, 2023 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 11, 2023 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 1, 2023 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 20, 2023 | Current report | SEC |
|---|
| SC 13G/A · Big-stake notice, amended | Jun 22, 2023 | Big-stake notice | SEC |
|---|
| S-8 POS | May 22, 2023 | Offer document | SEC |
|---|
| S-8 POS | May 22, 2023 | Offer document | SEC |
|---|
| S-8 POS | May 22, 2023 | Offer document | SEC |
|---|
| S-8 POS | May 22, 2023 | Offer document | SEC |
|---|
| 6-K · Report of a foreign issuer | May 17, 2023 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | May 17, 2023 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 26, 2023 | Current report | SEC |
|---|
| 20-F · Annual report | Apr 26, 2023 | Annual report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 26, 2023 | Current report | SEC |
|---|
| SC 13D/A · Big-stake notice, amended | Apr 18, 2023 | Big-stake notice | SEC |
|---|
| SC 13G · Big-stake notice | Apr 10, 2023 | Big-stake notice | SEC |
|---|
| 8-A12B · Registration of shares for listing on an exchange | Mar 27, 2023 | Other filings | SEC |
|---|
| S-8 POS | Mar 21, 2023 | Offer document | SEC |
|---|
| S-8 POS | Mar 21, 2023 | Offer document | SEC |
|---|
| S-8 POS | Mar 21, 2023 | Offer document | SEC |
|---|
| S-8 POS | Mar 21, 2023 | Offer document | SEC |
|---|
| 6-K · Report of a foreign issuer | Mar 21, 2023 | Current report | SEC |
|---|
| 424B3 · Prospectus | Feb 14, 2023 | Offer document | SEC |
|---|
| EFFECT · Notice that a registration is effective | Feb 14, 2023 | Other filings | SEC |
|---|
| CORRESP · Letter to the SEC | Feb 9, 2023 | Other filings | SEC |
|---|
| F-4/A | Feb 9, 2023 | Offer document | SEC |
|---|
| UPLOAD · Letter from the SEC | Feb 8, 2023 | Other filings | SEC |
|---|
| F-4 | Jan 31, 2023 | Offer document | SEC |
|---|
Open Filings · All of its filings on SEC EDGAR
Cap table
Built by 6ix from CASI Pharmaceuticals, Inc.’s releases
- Common shares
- 20,555,873
- Fully diluted
- 20,555,873
Fully diluted
| Line | Shares |
|---|
| Common shares | 20,555,873 |
|---|
Share count over time
| Count | Shares |
|---|
| Nov 22, 2026 | 20,555,873 |
|---|
Open Cap table
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|
| Alexander A Zukiwski | Global Chief Medical Officer · Since at least Mar 18, 2026 |
|---|
| Alex Wu | Director · Since at least Nov 4, 2026 |
|---|
| Chunhua Wang | Chief Operating Officer · Since at least Mar 18, 2026 |
|---|
| Frank Su | Director · Since at least Nov 4, 2026 |
|---|
| Hai Huang | Global Chief Commercial Ofcr · Since at least Mar 18, 2026 |
|---|
| James Huang | Director · Since at least Nov 5, 2026 |
|---|
| Junping Chen | Chief Medical Officer · Since at least Nov 5, 2026 |
|---|
| Kun Qian | Global Controller · Since at least Nov 4, 2026 |
|---|
| Thomas Folinsbee | Director · Since at least Mar 18, 2026 |
|---|
| Wei Gao | General Counsel · Since at least Nov 5, 2026 |
|---|
All 12 people
| Person | Seat |
|---|
| Wei-Wu He | Executive Chairman · Since at least Nov 5, 2026 |
|---|
| Xuebo Zeng | Director · Since at least Mar 18, 2026 |
|---|
Open People
Log in to ask 6ix AI your own questions about CASI Pharmaceuticals, Inc.